Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 74Hodgkin Disease 56Lymphoma 22Sarcoma 13Neoplasm Metastasis 11Leiomyosarcoma 8Uveal Melanoma 7Neoplasms 7Skin Neoplasms 6Neuroblastoma 4Sarcoma, Synovial 3Recurrence 3Solitary Fibrous Tumors 2Sarcoma, Alveolar Soft Part 2Hematologic Diseases 2HIV Infections 2Thyroid Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1

Interventions

binimetinib 2Sodium Chloride 2Aminolevulinic Acid 2palbociclib 1methyl 5-aminolevulinate 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Spironolactone 1Radiotherapy 1Radiation 1Photochemotherapy 1Paclitaxel 1Low-Level Light Therapy 1Leuprolide 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Fluorouracil 1Floderm topical cream 1Everolimus 1Equipment and Supplies 1Docetaxel 1Dacarbazine 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Diseases × Dacarbazine × Clear all
NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡